3 - 4 February
Presencial
2027 HCM
Summit LATAM
Advancing HCM Care Across Latin America
Scientific Leadership & Faculty
Academic Program
Preliminary subject to change
Registration & Networking
February 3
07:30 - 08:30
INTRODUCTION
• Evolution of the HCM concept
(Martin Maron - US)
• Clinical phenotypes of HCM
(Guillermo Llamas-Esperón - MX)
• Pathophysiology of HCM
(Fabio Fernandes - BRA)
• Expert Panel Discussion
February 3
08:30–09:30
EPIDEMIOLOGY
• International HCM registries
(Steve Ommen - US)
• LATAM HCM Registry
(Juan Pablo Costabel - ARG)
• HCM and multimorbidity
(Anjali Owens - US)
• Expert Panel Discussion
February 3
09:30–10:30
Coffee Break & Networking
February 3
10:30–11:00
GENETICS
• Genetics and sudden cardiac death risk (Roberto Barriales - SPAIN)
• Genetic counseling
(Blanca Ibarra- MEX)
• Gene-based therapies
(Eric Adler - US)
• Pregnancy planning in HCM
(Iacopo Olivotto- ITA)
• Expert Panel Discussion
February 3
11:00–12:00
CARDIAC IMAGING
• Echocardiography
(Julieta Morales - MX)
• Cardiac magnetic resonance
(Gabriela Meléndez - MX)
• Artificial intelligence in HCM diagnosis: hype or clinical reality?
(Ahmad Masri- US)
• Expert Panel Discussion
February 3
12:00–13:00
RISK STRATIFICATION
• ESC Guidelines
(Perry Elliot - UK)
• AHA/ACC Guidelines
(Steve Ommen- US)
• LATAM Consensus
(Enrique Berrios - MX)
• Expert Panel Discussion
February 3
13:00–14:00
Lunch
February 3
14:00–15:00
INDUSTRY SYMPOSIUM – PHENOCOPY DISORDERS
• Mixed ATTR phenotype
(Speaker pending)
• TTR gene-silencing therapies
(Speaker pending)
February 3
15:00–16:00
INDUSTRY SYMPOSIUM – PHENOCOPY DISORDERS
• Cardiac ATTR phenotype
(Speaker pending)
• TTR stabilizer therapies
(Speaker pending)
February 3
16:00–17:00
Opening Ceremony
Keynote Lecture (free):
Perry Elliot UK
February 3
17:00–18:00
Registration & Networking
February 4
07:30 - 08:30
PHARMACOLOGIC MANAGEMENT OF LVOT OBSTRUCTION
• Role of BB in obstructive and nonobstructive HCM (Juan David López- COL)
• Is there a role for SGLT2 inhibitors in HCM?
(Juan Pablo Costabel - ARG)
• Cardiac energy-modulating therapies
(Anjali Owens- US)
• Expert Panel Discussion
February 4
08:30–09:30
WHAT MATTERS IN HCM?
• What is the role of CPET in HCM
management? (Jorge Lara- MEX)
• What is the role of NT-proBNP and KCCQ in HCM management? (Fabio Fernandes-BRA)
• To treat or not to treat: asymptomatic HCM patients with outflow gradients. (Steve Ommen - US)
• Expert Panel Discussion
February 4
09:30–10:30
Coffee Break & Networking
February 4
10:30–11:00
SEPTAL REDUCTION THERAPIES
• Septal myectomy: contemporary evidence
(Eduard Quintana- SPAIN)
• Alcohol septal ablation: patient selection
(Eduardo Arias-MX)
• Management of mitral valve abnormalities
(Eduard Quintana- SPAIN)
• Expert Panel Discussion
February 4
11:00–12:00
INDUSTRY SYMPOSIUM – MYOSIN INHIBITION
• Mavacamten in obstructive HCM
(Roberto Barriales - SPAIN)
• Mavacamten in adolescents
(Iacopo Olivotto- ITA)
• Real-world clinical experience
(Ahmad Masri- US)
February 4
12:00–13:00
INDUSTRY SYMPOSIUM – MYOSIN INHIBITION
• Aficamten in obstructive HCM and non-obstructive HCM (Martin Maron US)
February 4
13:00–14:00
Lunch
February 4
14:00–15:00
NEW THERAPHIES: EDENWISE, BRAVEHEART
• Pending. Could be substitute for:
ATRIAL FIBRILLATION & END-STAGE HCM
• Rhythm management (Ethan Rowin US)
• LVAD and heart transplantation (Antonio Jordan US)
•End stage heart failure therapies (Ethan Rowin US)
• Expert Panel Discussion
February 4
15:00–16:00
DEBATES:
Fabio Fernandes (BRA), Juan Pablo Costabel (ARG), Juan David Lopez (COL), Enrique Berrios (MEX), Guillermo Llamas (MEX)
Judges: Martin Maron (US), Roberto Barriales (SPAIN).
-
Sports eligibility in HCM
-
Are CMI now First Line for oHCM
February 4
16:00–17:00
Closing Ceremony
Keynote Lecture (free):
Martin Maron US
February 4
17:00–18:00
